Durect Corporation (DRRX) - Total Assets

Latest as of June 2025: $12.48 Million USD

Based on the latest financial reports, Durect Corporation (DRRX) holds total assets worth $12.48 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check DRRX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Durect Corporation - Total Assets Trend (1999–2024)

This chart illustrates how Durect Corporation's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Durect Corporation to see how much of total assets are deployed in long-term investments.

Durect Corporation - Asset Composition Analysis

Current Asset Composition (December 2024)

Durect Corporation's total assets of $12.48 Million consist of 71.8% current assets and 28.2% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 60.0%
Accounts Receivable $453.00K 2.5%
Inventory $106.00K 0.6%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $0.00 0.0%
Goodwill $2.73 Million 14.9%

Asset Composition Trend (1999–2024)

This chart illustrates how Durect Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Durect Corporation (DRRX) market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Durect Corporation's current assets represent 71.8% of total assets in 2024, a decrease from 77.8% in 1999.
  • Cash Position: Cash and equivalents constituted 60.0% of total assets in 2024, up from 17.2% in 1999.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 6.0% in 1999.
  • Asset Diversification: The largest asset category is goodwill at 14.9% of total assets.

Durect Corporation Competitors by Total Assets

Key competitors of Durect Corporation based on total assets are shown below.

Company Country Total Assets
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
Huadong Medicine Co Ltd
SHE:000963
China CN¥39.93 Billion
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
China CN¥10.37 Billion
Walvax BioTech
SHE:300142
China CN¥11.13 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
China CN¥1.41 Billion
Celltrion Pharm Inc
KQ:068760
Korea ₩745.80 Billion
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
China CN¥2.53 Billion

Durect Corporation - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.98 0.91 5.95
Quick Ratio 0.95 0.80 5.57
Cash Ratio 0.00 0.00 0.00
Working Capital $-121.00K $-1.98 Million $47.31 Million

Durect Corporation - Advanced Valuation Insights

This section examines the relationship between Durect Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 17.03
Latest Market Cap to Assets Ratio 3.23
Asset Growth Rate (YoY) -59.4%
Total Assets $18.35 Million
Market Capitalization $59.31 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Durect Corporation's assets at a significant premium (3.23x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Durect Corporation's assets decreased by 59.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Durect Corporation (1999–2024)

The table below shows the annual total assets of Durect Corporation from 1999 to 2024.

Year Total Assets Change
2024-12-31 $18.35 Million -59.39%
2023-12-31 $45.19 Million -24.81%
2022-12-31 $60.10 Million -34.67%
2021-12-31 $91.99 Million +21.61%
2020-12-31 $75.64 Million -12.07%
2019-12-31 $86.02 Million +72.04%
2018-12-31 $50.00 Million -5.86%
2017-12-31 $53.11 Million +31.12%
2016-12-31 $40.51 Million -13.39%
2015-12-31 $46.77 Million -6.61%
2014-12-31 $50.08 Million +22.69%
2013-12-31 $40.82 Million -11.14%
2012-12-31 $45.94 Million -6.63%
2011-12-31 $49.20 Million -27.18%
2010-12-31 $67.56 Million +16.18%
2009-12-31 $58.15 Million -22.33%
2008-12-31 $74.87 Million -10.89%
2007-12-31 $84.02 Million -18.02%
2006-12-31 $102.48 Million -12.71%
2005-12-31 $117.41 Million +37.38%
2004-12-31 $85.47 Million -23.97%
2003-12-31 $112.41 Million +54.04%
2002-12-31 $72.97 Million -30.47%
2001-12-31 $104.94 Million -12.99%
2000-12-31 $120.61 Million +436.94%
1999-12-31 $22.46 Million --

About Durect Corporation

NASDAQ:DRRX USA Drug Manufacturers - Specialty & Generic
Market Cap
$59.31 Million
Market Cap Rank
#21312 Global
#4718 in USA
Share Price
$1.91
Change (1 day)
-1.04%
52-Week Range
$0.52 - $1.96
All Time High
$38.00
About

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more